The BENDIP study demonstrated that neuropathic symptoms, measured using the NIS as the primary endpoint, improved after 6 weeks of treatment with benfotiamine at a dose of 300 mg twice daily (no improvement was observed with 300 mg once daily) [71]
No dosage adjustment of MOUNJARO is recommended for patients with renal impairment
June 12, 2025 5:16 View More Unlocking the Gut-Body Connection: The Surprising Links Between Digestion, Immunity & Mental Health In this podcast episode, host McCall McPherson is joined by two industry-leading guests in the microbiome and wellness space: Tina Anderson, CEO and Co-Founder of Just Thrive Probiotic & Antioxidant, and Kiran Krishnan, Microbiologist and Co-Founder of Microbiome Labs
Thats a dealbreaker for some people
D-limonene suppresses doxorubicin-induced oxidative stress and inflammation via repression of COX-2, iNOS, and NFB in kidneys of Wistar rats